Vagal hyperactivity due to ventromedial hypothalamic lesions increases adiponectin production and release.
In obese humans and animals, adiponectin production and release in adipose tissue are downregulated by feedback inhibition, resulting in decreased serum adiponectin. We investigated adiponectin production and release in ventromedial hypothalamic (VMH)-lesioned animals. VMH-lesioned mice showed significant increases in food intake and body weight gain, with hyperinsulinemia and hyperleptinemia at 1 and 4 weeks after VMH-lesioning. Serum adiponectin was elevated in VMH-lesioned mice at 1 and 4 weeks, despite adipocyte hypertrophy in subcutaneous and visceral adipose tissues and increased body fat. Adiponectin production and mRNA were also increased in both adipose tissues in VMH-lesioned mice at 1 week. These results were replicated in VMH-lesioned rats at 1 week. Daily atropine administration for 5 days or subdiaphragmatic vagotomy completely reversed the body weight gain and eliminated the increased adiponectin production and release in these rats, with reversal to a normal serum adiponectin level. Parasympathetic nerve activation by carbachol infusion for 5 days in rats increased serum adiponectin, with increased adiponectin production in visceral and subcutaneous adipose tissues without changes of body weight. These results demonstrate that activation of the parasympathetic nerve by VMH lesions stimulates production of adiponectin in visceral and subcutaneous adipose tissues and adiponectin release, resulting in elevated serum adiponectin.
Faculty of Health Science, Kiryu University, Midori, Gunma, Japan.
Yoko
Y
Suzuki
Hiroyuki
H
Shimizu
Noriko
N
Ishizuka
Naoto
N
Kubota
Tetsuya
T
Kubota
Akira
A
Senoo
Haruaki
H
Kageyama
Toshimasa
T
Osaka
Satoshi
S
Hirako
Hyoun-Ju
HJ
Kim
Akiyo
A
Matsumoto
Seiji
S
Shioda
Masatomo
M
Mori
Takashi
T
Kadowaki
Shuji
S
Inoue
D052242:Adiponectin / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001786:Blood Glucose; D002217:Carbachol / Q000494:pharmacology; D005260:Female; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D051379:Mice; D016627:Oxidopamine / Q000494:pharmacology; D010275:Parasympathetic Nervous System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014630:Vagus Nerve / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D014697:Ventromedial Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*
D052242:Adiponectin; D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D001285:Atropine; D016627:Oxidopamine; D002217:Carbachol